The Cleveland Clinic Abu Dhabi (كليفلاند كلينك أبو ظبي, known as CCAD) is a multi specialty hospital located in Abu Dhabi, United Arab Emirates. The 364 bed luxury hospital, part of Cleveland Clinic Foundation, USA, has been open to the public since May 2015.
In 2024, a comprehensive framework for the screening, diagnosis, and management of metabolic dysfunction–associated steatotic liver disease (MASLD) was incorporated in the EASL-EASD-EASO clinical practice guidelines. However, physicians often face barriers applying these recommendations in routine clinical care, especially in the Southeastern Europe, Middle East, and Africa (SEEMEA) region. As a multidisciplinary group of physicians involved in MASLD and metabolic dysfunction-associated steatohepatitis (MASH) management, our objective is to provide a practice-oriented roadmap including practical and educational considerations beyond the hepatology field that could improve patient care and support implementation of clinical guidance within the SEEMEA region. This work is informed by a narrative review and expert input obtained through structured discussions, to examine the status quo and identify key gaps in the MASLD/MASH management, unravelling the patient journey from screening and diagnosis to treatment and follow-up. Furthermore, we advise on priorities on screening triggers and, considering the limited availability of vibration-controlled transient elastography (VCTE), discuss alternative approaches to achieve accurate and timely diagnosis. Finally, following the approval of resmetirom and semaglutide 2.4 mg for MASH treatment, we review the evolving pharmacotherapy landscape and propose a “blueprint” for a specialised MASLD clinic, suggesting mandatory and optional facilities for optimised care.
Gastrojejunal (GJ) anastomotic strictures are a challenging complication following Roux-en-Y gastric bypass (RYGB) and may be refractory to conventional balloon dilation. Lumen-apposing metal stents (LAMS) provide anchored, wide-caliber support that may treat strictures, yet long-term outcomes remain variable, and stent migration is a concern. This study evaluates the clinical effectiveness and safety of LAMS with or without concurrent endoscopic stricturoplasty in patients with GJ strictures. We conducted a single-center retrospective cohort study of patients with GJ strictures who underwent LAMS placement between January 2020 and May 2025. Patients were stratified by whether concurrent endoscopic stricturoplasty was performed at the time of stent placement. Clinical success was defined as symptom resolution without need for reintervention. The primary outcome was long-term clinical success (> 90 days). Secondary outcomes included short-term clinical success (≤ 30 days), stent dwell time, procedure duration, stent migration, and adverse events. Twenty-five patients were included (mean age 46.8 ± 12.9 years; 76
To quantify serial central subfield thickness (CSFT) changes after slow-coagulation transscleral cyclophotocoagulation (SC-TSCPC) for glaucoma, estimate the incidence of OCT-confirmed cystoid macular edema (CME), and explore baseline factors associated with CME, including diabetes and prior diabetic macular edema. Retrospective cohort of 31 eyes undergoing SC-TSCPC for glaucoma with OCT imaging preoperatively and postoperatively at 1, 3, 6, 9, and 12 months and at last follow-up (range 9–30 months). OCT-confirmed CME was defined as cystoid intraretinal changes on OCT; increased CSFT alone was not classified as CME. Changes over time were assessed with non-parametric repeated-measures testing, and subgroup comparisons were exploratory and univariate because of the small sample size. Mean baseline CSFT was 279 ± 25 um and peaked at 355 ± 153 um at 1 month, then declined to 293 ± 25 um at 12 months (p < 0.001 across visits). Mean CSFT at last follow-up remained higher than baseline (294 ± 25 vs. 279 ± 25 um; p < 0.001). OCT-confirmed CME developed in 8/31 eyes (25.8
This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA(2)LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), with the participation of 210 delegates from 107 national and international societies, from 59 countries. The consensus conference was held on December 6th, 2024. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell-driven disease, defined by a rapid appearance of wheals, angioedema, or both. The lifetime prevalence of acute urticaria is estimated to be approximately 20%. Chronic urticaria, categorized as either chronic spontaneous urticaria or chronic inducible urticaria, is disabling, impairs quality of life, and affects performance at work and school, however, novel therapies are available. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.
Arabic remains one of the most underrepresented languages in natural language processing research, particularly in medical applications, due to the limited availability of open-source data and benchmarks. The lack of resources hinders efforts to evaluate and advance the multilingual capabilities of Large Language Models (LLMs). In this paper, we introduce MedAraBench, a large-scale dataset consisting of Arabic multiple-choice question-answer pairs across various medical specialties. We constructed the dataset by manually digitizing a large repository of academic materials created by medical professionals in the Arabic-speaking region. We then conducted extensive preprocessing and split the dataset into training and test sets to support future research efforts in the area. To assess the quality of the data, we adopted two frameworks, namely expert human evaluation and LLM-as-a-judge. Our dataset is diverse and of high quality, spanning 19 specialties and five difficulty levels. For benchmarking purposes, we assessed the performance of eight state-of-the-art open-source and proprietary models, such as GPT-5, Gemini 2.0 Flash, and Claude 4-Sonnet. Our findings highlight the need for further domain-specific enhancements. We release the dataset and evaluation scripts to broaden the diversity of medical data benchmarks, expand the scope of evaluation suites for LLMs, and enhance the multilingual capabilities of models for deployment in clinical settings.
